 "Suven's third molecule enters clinical trial phase")
The NCE is a potential drug for treatment of cognitive dysfunction associated with Alzheimer's disease and other dementia.
"We are very pleased that the third compound from our pipeline of molecules in CNS has moved into a clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia, a high unmet medical need which has huge market potential globally," Venkat Jasti, CEO of Suven said in a statement.
Hyderabad-based Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products.
Suven has three clinical stage compounds including a phase-2 initiated candidate.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app